Connor, Clark & Lunn Investment Management (CC&L)
KRRO icon

Connor, Clark & Lunn Investment Management (CC&L)’s Korro Bio KRRO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,240
Closed -$131K – 1123
2022
Q1 		$131K Buy
+1,240
New +$237K ﹤0.01% 966

Other funds holding KRRO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KRRO Position: Q2 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Korro Bio (KRRO) in Q2 2022, closing a stake of 1,240 shares — an estimated $131K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KRRO in Q1 2022 and held it in 1 quarter. The position peaked at $131K in Q1 2022. 58 funds tracked by Wall St. Rank hold KRRO as of Q2 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Korro Bio position as of Q2 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 1,240 Korro Bio shares in Q2 2022, an estimated $131K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Korro Bio in Q1 2022 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Korro Bio position peaked at $131K in Q1 2022.
  • 58 funds tracked by Wall St. Rank held Korro Bio as of Q2 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2022, filed 5 Aug 2022.